Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Redmond

Showing results (181-190 of 205) with videos related to

Pageof 21
Sort By:
Journal for Immunotherapy of Cancer|January 28, 2022
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancerBrie Chun, Joanna Pucilowska, ShuChing Chang, et al.
Disease Models & Mechanisms|February 3, 2022
Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional dataBaharak Ahmaderaghi, Raheleh Amirkhah, James Jackson, et al.
Nature Communications|March 1, 2014
Differential affinity of FLIP and procaspase 8 for FADD's DED binding surfaces regulates DISC assemblyJ Majkut, M Sgobba, C Holohan, et al.
Journal for Immunotherapy of Cancer|June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapyRyan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
Cancer Immunology Research|January 27, 2021
Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor GrowthMark D Badeaux, Annah S Rolig, Giulia Agnello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2015
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal CancerPhilip D Dunne, Sonali Dasgupta, Jaine K Blayney, et al.
Journal for Immunotherapy of Cancer|April 10, 2021
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitorBrendan D Curti, Yoshinobu Koguchi, Rom S Leidner, et al.
Seminars in Oncology|November 16, 2010
Signaling through OX40 enhances antitumor immunityShawn M Jensen, Levi D Maston, Michael J Gough, et al.
Cancer Research Communications|July 18, 2024
Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional SignaturesUmair Mahmood, Andrew Blake, Sanjay Rathee, et al.
JCI Insight|June 30, 2026
A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcomaJianguo Huang, Xingliang Liu, Warren Floyd, et al.
Pageof 21

Showing results (181-190 of 205) with videos related to

Sort By:
Pageof 21
Journal for Immunotherapy of Cancer|January 28, 2022
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancerBrie Chun, Joanna Pucilowska, ShuChing Chang, et al.
Disease Models & Mechanisms|February 3, 2022
Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional dataBaharak Ahmaderaghi, Raheleh Amirkhah, James Jackson, et al.
Nature Communications|March 1, 2014
Differential affinity of FLIP and procaspase 8 for FADD's DED binding surfaces regulates DISC assemblyJ Majkut, M Sgobba, C Holohan, et al.
Journal for Immunotherapy of Cancer|June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapyRyan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
Cancer Immunology Research|January 27, 2021
Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor GrowthMark D Badeaux, Annah S Rolig, Giulia Agnello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2015
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal CancerPhilip D Dunne, Sonali Dasgupta, Jaine K Blayney, et al.
Journal for Immunotherapy of Cancer|April 10, 2021
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitorBrendan D Curti, Yoshinobu Koguchi, Rom S Leidner, et al.
Seminars in Oncology|November 16, 2010
Signaling through OX40 enhances antitumor immunityShawn M Jensen, Levi D Maston, Michael J Gough, et al.
Cancer Research Communications|July 18, 2024
Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional SignaturesUmair Mahmood, Andrew Blake, Sanjay Rathee, et al.
JCI Insight|June 30, 2026
A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcomaJianguo Huang, Xingliang Liu, Warren Floyd, et al.
Pageof 21